Connect with us

autism

Study: Early cannabis use in pregnancy doesn’t predict autism

Published

on


Cannabis use during pregnancy has been increasing in the US, and many people may be wondering what impacts this trend could have on children. Some previous research has pointed towards the possibility that prenatal cannabis exposure could increase the likelihood of having autistic children. But a recent study—one of the largest ever conducted on cannabis and autism—found that cannabis exposure in early pregnancy did not lead to higher odds of an autism diagnosis.

What is autism?

Autism is classified as a developmental disorder. It impacts how individuals interact with others, communicate, learn, and experience life. One in 36 Americans are diagnosed with autism; symptoms usually appear during the first two years of a person’s life. Autism is also a spectrum condition—it encompasses a wide variety of different symptoms that an individual might experience, and different levels of health care support may be needed.

Some of the challenges that autistic people might face include having a style of communication that non-autistic people have trouble understanding, having sensory issues because of heightened or reduced sensory perception, and having more repetitive or restricted patterns of behavior than non-autistic peers.

Related

Minnesota OKs Medical Marijuana for Autism, Sleep Apnea

While medical literature classifies autism as a disorder, many autistic advocates point out that many of the “symptoms” of autism are not inherently problematic or disordered; they simply clash with non-autistic expectations, leaving autistic people marginalized. 

Previous research on cannabis exposure and autism

The recent study, conducted by researchers from Kaiser Permanente and UC San Francisco, evaluated whether cannabis use in early pregnancy could increase the likelihood of a woman giving birth to an autistic child. Autism has been linked to a variety of potential environmental causes, but most research points towards genetics as the primary cause.  

One study, published in 2020, did find an association between prenatal cannabis use and autism, leading to questions about whether cannabis use could cause autism. However, otherstudies found no associations. Unfortunately, those studies utilized self-reporting methods, which may have skewed the results due to a potential underreporting of cannabis use. 

Researchers in the recent Kaiser / UCSF used more rigorous methods to determine whether prenatal cannabis use caused higher rates of autism in children.

Studying prenatal cannabis and autism

This recent study was one of the largest ever done on the topic (it included 178,948 pregnancies), but it also utilized a more robust data set for cannabis use and autism.

This recent study was one of the largest ever done on the topic (it included 178,948 pregnancies), but it also utilized a more robust data set for cannabis use and autism. The study incorporated information from Kaiser Permanente Northern California’s integrated health-care system, which universally screens pregnant individuals for cannabis use—via both self-reporting and a urine toxicology test. Kaiser also routinely screens and assesses children for autism.

Shop highly rated dispensaries near you

Showing you dispensaries near

See all dispensaries

The researchers also included related factors in their analysis like sociodemographic data, the additional medications and substances that a mother consumes, and general health conditions.

Prenatal cannabis use not associated with autism

While an initial analysis appeared to indicate an association between autism and prenatal cannabis use, the association disappeared after adjusting for factors like sociodemographic characteristics and the medical conditions of the mother.

This lack of association suggests that mothers who use cannabis during pregnancy are more likely to have autistic children—not because of the cannabis itself, but because of other factors that also increase likelihood of cannabis use. 

While the researchers don’t identify those specific factors, these results shouldn’t be that surprising: For one, Autism has high hereditary rates. Furthermore, cannabis is sometimes used as an effective treatment for symptoms of autism. Separate studies have noted that autistic individuals tend to have lower levels of endocannabinoids in their bodies, which could suggest an impairment of the endocannabinoid system. 

Mothers with autism—or other conditions tied to the same genes as autism—are more likely to both use cannabis and have autistic children; this correlation may help explain the initial results of the study. Still, only more research will offer conclusive answers to these questions. 

Limitations and future research

This study used a strong methodology, with a large and diverse data set. Still, it was limited by the fact that cannabis use was only measured in early pregnancy. Future studies should measure cannabis use throughout pregnancy, and ideally include information like the methods and dosing of the cannabis itself.

While this study suggests prenatal cannabis use is not associated with autism, the authors nonetheless caution that there is evidence that cannabis can impact development in other ways and should be avoided during pregnancy. 



Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

AJNA BioSciences

FDA clears DeFloria’s cannabis-based autism treatment for phase 2 trial

Published

on



DeFloria said Monday that the Federal Drug Administration has stamped the firm’s application to begin a Phase 2 clinical trial for AJA001, an oral cannabinoid drug being made to treat symptoms of autism spectrum disorder.

The company, which was formed in 2023 as a joint-venture among Charlotte’s Web (OTCQX: CWBHF), Ajna BioSciences and British American Tobacco (NYSE: BTI), plans to start the trial by mid-year 2025. BAT holds an equity stake through 200,000 preferred units following an initial $10 million investment, with Charlotte’s Web and Ajna each holding 400,000 voting common units.

“IND submission for AJA001 and the initiation of the Phase 2 study in the US mark a historic moment in our mission to develop a systemically absorbed botanical drug therapy that meets guidelines established by the FDA for advanced clinical testing,” DeFloria CEO Jared Stanley said in a statement.

The planned 12-week study will test the drug on 60 adolescents and young adults with autism, ages 13-29, to establish dosing levels for future larger studies.

AJA001 was made using Charlotte’s Web’s hemp genetics and contains full spectrum hemp extract with cannabidiol (CBD) as the primary ingredient.

According to DeFloria, autism affects as many as 1 in 36 children and represents a $4 billion market in the U.S. that’s growing more than 4% annually. Current treatment options are limited to just two approved drugs – antipsychotics that often cause side effects and compliance problems.

“There is strong data supporting the potential efficacy of cannabinoids to treat autism spectrum disorder, offering what we hope will be a safer and more effective therapy than what is currently available,” said Orrin Devinsky, MD and Chief Medical Advisor for DeFloria.

The drug’s development builds on the foundation of Charlotte’s Web’s origin story.

“For more than 15 years, my family and our team have been laying the foundation for this botanical drug,” said Joel Stanley, CEO of Ajna BioSciences and Chairman of DeFloria’s Board. “Charlotte Figi’s story, shared by Dr. Sanjay Gupta on CNN, put the benefits of cannabinoids on the world’s radar and sparked a movement.”

Charlotte’s Web CEO Bill Morachnick emphasized the significance of this milestone in extending the company’s leadership “from the consumer sector into the regulated medical sector.”

DeFloria also plans to conduct a separate pediatric study of AJA001 in Australia in 2025.



Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading

autism

DeFloria advances cannabis-based autism drug through early trial

Published

on



DeFloria announced Thursday that its experimental cannabis-based drug for autism spectrum disorder showed positive early results, with patients tolerating the treatment well across multiple dose levels.

The drug, AJA001, being developed as a multi-compound hemp extract with a full spectrum of cannabinoids, demonstrated safety at daily doses up to 660 mg when given twice per day, according to results presented at a neuropsychopharmacology conference in Phoenix. The Phase 1 trial included 70 healthy volunteers ranging from 19 to 55 years old.

“We are extremely encouraged by these results,” Marcel O. Bonn-Miller, Ph.D., chief scientific officer at Charlotte’s Web Holdings Inc. and DeFloria board member, said in a statement. He noted that the drug achieved blood concentration levels matching or exceeding existing cannabis-based medicines like Epidiolex.

The Colorado-based company, formed in April as a joint venture between Charlotte’s Web (OTCQX: CWBHF), Ajna BioSciences and British American Tobacco (NYSE: BTI), aims to help address a significant unmet need. About 1 in 36 children may have autism spectrum disorder, according to recent CDC data cited by the company. BAT holds an equity stake through 200,000 preferred units following an initial $10 million investment, with Charlotte’s Web and Ajna each holding 400,000 voting common units.

Common side effects included drowsiness, anxiety, dizziness and headaches, DeFloria reported. One participant receiving a higher 906.4 mg dose experienced anxiety that resolved within a day.

The drug combines multiple cannabinoids from hemp plants, including carefully controlled amounts of CBD and THC. The trial results support testing doses containing up to 395 mg CBD and 15 mg THC daily in future studies.

“Currently available treatments for ASD are not well tolerated, making patient compliance a challenge,” said Jared Stanley, DeFloria’s CEO.

The company is preparing to submit the Phase 1 trial data as part of its Investigational New Drug application to the FDA. If approved, DeFloria plans to explore the drug’s potential for addressing behavioral symptoms and improving quality of life for individuals with autism spectrum disorder in two Phase 2 trials starting in the second quarter of 2025.

The treatment uses hemp extract from Charlotte’s Web’s proprietary CW1AS1 cannabis strain. If successful in later trials, AJA001 could become one of the first FDA-approved botanical drugs derived from hemp for autism spectrum disorder.

“DeFloria’s Phase 1 results validate our strategic vision of advancing botanical science through pharmaceutical pathways,” said Bill Morachnick, CEO of Charlotte’s Web. “This milestone demonstrates how our proprietary genetics and expertise in hemp cultivation can create significant value beyond our core wellness business.”



Source link

mscannabiz.com
Author: mscannabiz.com

MScannaBIZ for all you Mississippi Cannabis News and Information.

Continue Reading
featured37 minutes ago

RollPros Launches Blackbird XXL: The First-Ever Automated Blunt Rolling Machine

featured2 hours ago

Ozzy Osbourne, Parkinson’s and the Promise of Magic Mushrooms: Could They Have Helped?

featured3 hours ago

Pennsylvania: Reading City Council Adopts Municipal Decriminalization Ordinance

video3 hours ago

VIDEO: Guest Smokes Weed on Mario Kart After Attraction Breaks Down At Universal Studios Hollywood

featured4 hours ago

Federal Report Shows Youth Marijuana Use ‘Remained Stable’ Even As More States Legalized In Recent Years

video4 hours ago

Cannabis ballot initiative brings lawsuit to Menominee

featured5 hours ago

Proposed DOJ Rule Says Marijuana Users Likely Wouldn’t Be Eligible To Have Gun Rights Restored

video6 hours ago

Kentucky medical marijuana cultivator brings in half-grown plants to speed harvest

featured6 hours ago

Federal Researchers Claim First-Ever Detection Of Cannabinoids In Human Breath After Use Of Marijuana Edibles

featured7 hours ago

BREEDING FOR BIG BUDS (1986)

featured10 hours ago

New DEA Admin Sidelines Cannabis Rescheduling Despite Earlier Promises

featured11 hours ago

New Rules in New Zealand Place Strict Guidelines on Medical Cannabis ‘Advertising’ 

video12 hours ago

South Beloit blood donors get marijuana products for their contribution

featured12 hours ago

Oklahoma Campaign to Legalize Adult-Use Cannabis Will Begin Collecting Signatures Next Month 

video13 hours ago

Bellbrook leaders pass ordinance banning marijuana sales

featured13 hours ago

PackworldUSA Highlights Versatile, Precision-Driven 3400 Series Heat Sealer for Cannabis Applications

featured14 hours ago

Federal Court Sides With Safe Drug Consumption Site, Saying Religious Protections Apply

featured15 hours ago

Trump’s New DEA Administrator Omits Cannabis Rescheduling From Top Priorities

featured16 hours ago

High Times, RAW and hhemp.co Forge New Era of Pre‑Rolls, Vapes & Hemp Products

featured18 hours ago

Bill To Ban Hemp Products With THC Is Filed In Texas House, As Governor Continues To Call For Regulations Instead

video18 hours ago

Illness linked to cannabis use sending more patients to the hospital, including NC woman

featured19 hours ago

Chicagoland Cookies Dispensary Opens in Illinois

featured20 hours ago

Is the Wait Over for Colombian Patients? Government May Allow Sale of Medical Cannabis Flowers

featured21 hours ago

NORML Remembers Richard Lee – NORML

California Cannabis Updates1 year ago

Alert: Department of Cannabis Control updates data dashboards with full data for 2023 

Breaking News1 year ago

Connecticut Appoints The US’s First Cannabis Ombudsperson – Yes there is a pun in there and I’m Sure Erin Kirk Is Going To Hear It More Than Once!

best list12 months ago

5 best CBD creams of 2024 by Leafly

Business10 months ago

EU initiative begins bid to open access to psychedelic therapies

Bay Smokes1 year ago

Free delta-9 gummies from Bay Smokes

cbd1 year ago

New Study Analyzes the Effects of THCV, CBD on Weight Loss

autoflower seeds10 months ago

5 best autoflower seed banks of 2024 by Leafly

California1 year ago

May 2024 Leafly HighLight: Pink Runtz strain

Breaking News1 year ago

Curaleaf Start Process Of Getting Their Claws Into The UK’s National Health System – With Former MP (Resigned Today 30/5/24) As The Front Man

Mississippi Cannabis News1 year ago

Mississippi city official pleads guilty to selling fake CBD products

cannabis brands10 months ago

Discover New York’s dankest cannabis brands [September 2024]

Mississippi Cannabis News1 year ago

Local medical cannabis dispensary reacts to MSDH pulling Rapid Analytics License – WLBT

Mississippi Cannabis News1 year ago

Horn Lake denies cannabis dispensary request to allow sale of drug paraphernalia and Sunday sales | News

Hemp1 year ago

Press Release: CANNRA Calls for Farm Bill to Clarify Existing State Authority to Regulate Hemp Products

Breaking News1 year ago

Nevada CCB to Accept Applications for Cannabis Establishments in White Pine County – “Only one cultivation and one production license will be awarded in White Pine County”

best list1 year ago

5 best THC drinks of 2024 by Leafly

Arkansas10 months ago

The Daily Hit: October 2, 2024

best list1 year ago

6 best CBD gummies of 2024 by Leafly

best list1 year ago

5 best delta-9 THC gummies of 2024 by Leafly

Breaking News1 year ago

Weekly Update: Monday, May 13, 2024 including, New Guide for Renewals & May Board meeting application deadline

Mississippi Cannabis News1 year ago

People In This State Googled ‘Medical Marijuana’ The Most, Study Shows

Breaking News1 year ago

PRESS RELEASE : Justice Department Submits Proposed Regulation to Reschedule Marijuana

Asia Pacific & Australia1 year ago

Thailand: Pro-cannabis advocates rally ahead of the government’s plan to recriminalize the plant

California Cannabis Updates1 year ago

Press Release: May 9, STIIIZY and Healing Urban Barrios hosted an Expungement Clinic & Second Chance Resource Fair

Trending